CURRENT
ISSUE
1559

The FDA has approved two subcutaneously injected calcitonin gene-related peptide (CGRP) antagonists, fremanezumab-vfrm (Ajovy – Teva) and galcanezumab-gnlm (Emgality – Lilly), for migraine prevention in adults. Fremanezumab and galcanezumab are the second and third subcutaneously injected monoclonal antibodies that target the CGRP pathway to be approved by the FDA for this indication; erenumab-aooe (Aimovig), which targets the CGRP receptor, was the first.1

MIGRAINE PREVENTION — Patients with frequent or severe migraine headaches and those who cannot take...  Continue reading

More from Issue 1559
Previous Issue: 1558      October 22, 2018
Coming Soon
Vaccines for Travel
Low-Dose Rivaroxaban (Xarelto) for Secondary Cardiovascular Prevention
Baloxavir (Xofluza) for Influenza
Aprepitant Emulsion (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting
Search
Subscribe
Conversation
Follow us  facebook        Email Alerts
 Tweets
FROM
ISSUE
1559

The FDA has approved the new aminoglycoside antibiotic plazomicin (Zemdri – Achaogen) for IV treatment of adults with complicated urinary tract infections (cUTIs). Plazomicin is active against multi-drug-resistant Enterobacteriaceae, including strains resistant to other aminoglycosides.

STANDARD TREATMENT OF cUTI — Complicated UTIs (pyuria with a documented pathogen in urine or blood and systemic signs of infection) typically occur in patients with comorbidities such as indwelling urinary catheters. Pyelonephritis is considered a cUTI. Generally, cUTIs are caused by gram-negative bacilli including Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Pseudomonas aeruginosa. An oral fluoroquinolone such as ciprofloxacin (Cipro, and ... Continue reading